Bevacizumab BS IV infusion 100mg “CTNK”, manufactured by Nippon Kayaku, contains Bevacizumab (genetical recombination) [Bevacizumab follow-on 4]. This monoclonal antibody is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A), reducing tumor blood supply. It is supplied as 100mg in 4mL per bottle, with YJ code 4291463A1020.
Bevacizumab BS IV infusion 100mg “CTNK”
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →